【ChiCTR2100049126】Efficacy of Thiamine in Patients with Clinically Suspected Dry Beriberi: An Open Labeled Hospital Based Study in Bangladesh
ChiCTR2100049126
结束
/
/
/
2021-07-21
/
/
dry beriberi
Efficacy of Thiamine in Patients with Clinically Suspected Dry Beriberi: An Open Labeled Hospital Based Study in Bangladesh
Efficacy of Thiamine in Patients with Clinically Suspected Dry Beriberi: An Open Labeled Hospital Based Study in Bangladesh
4203
General objective: To evaluate the efficacy of Thiamine in patients with suspected / possible dry beriberi Specific objectives: 1. To describe the socio-demographic profile of patients; 2. To categorize the patients according to their presenting symptoms and signs; 3. To assess and compare pre and post treatment neurological features.
单臂
回顾性研究
N/A
N/A
self funding
/
55
/
2018-07-01
2018-06-30
/
1. Any person admitted to CMCH as a Suspected/Possible dry-beriberi. Risk factors + at least 2 of the following signs: Risk factors include Imbalanced diet (diet poor in thiamine/rich in carbohydrate or anti-thiamine factors), malnutrition, alcoholism, GIT surgery, chronic diarrhoea, chronic vomiting, pregnancy or history of recent delivery, chronic. diuretics use, renal dialysis, total parenteral nutrition. 1) Muscle weakness of upper and or lower limb (less than grade 5 power in MRC scale); 2) Positive sensory symptoms (burning, tingling or pain); 3) Objective sensory deficit (pain, touch, position, vibration sense); 4) Absent or reduced deep tendon reflexes; 5) Positive squat test (unable to rise after squatting without help);6) Leg swelling; 2. Aged 18 years and above.；
请登录查看1. Patients with isolated cardiac/wet beriberi; 2. Patient with known causes of peripheral neuropathy such as Diabetic, hereditary, Demyelinating (GBS, CIDP), metabolic (hepatic/renal impairment), drugs (e.g. INH, Ethambutol, Phenytoin, Metronidazole, Dapsone etc.) Toxin (As ,OPC, Pb ,Hg except alcohol) etc.; 3. Patients refuse to participate.；
请登录查看Dr. Nayema Masrura
4203
Dr. Nayema Masrura的其他临床试验
孟加拉国热带病与传染病研究所的其他临床试验
最新临床资讯
-
大鹏制药临床III期成功
新药说2026-08-13
-
新一代 EGFR-TKI 首个全球 III 期成功
丁香园 Insight 数据库2026-08-13
-
体外诊断原料网2026-08-13
-
佰傲谷BioValley2026-08-13
-
久有基金2026-08-13
-
重庆宸安生物2026-08-13
-
UmabsDB2026-08-13
-
希格生科2026-08-13
-
bioSeedin柏思荟2026-08-13
-
智飞智讯2026-08-13
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 20 8
-
摩熵咨询 34 28
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 36
-
摩熵咨询 28 39
-
摩熵咨询 34 18
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29